OncRef

Clinical Trial: NCT04300556

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Status:

RECRUITING

Phase:

Phase 1

Lead Sponsor:Eisai Inc.
Information Provided By:Eisai Inc.
Last Update Posted:2026-06-04

Study Overview

Brief Summary

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer [OC], endometrial cancer [EC], non-small cell lung carcinoma [NSCLC], triple-negative breast cancer [TNBC]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecteribulin (MORAb-202) in participants with OC and EC at selected doses and to further evaluate the safety and tolerability of farletuzumab ecteribulin (MORAb-202) and (3) dose-optimization part. (divided in two parts: Part A [OC and EC participants] and Part B [OC only]): Part A: to evaluate other farletuzumab ecteribulin (MORAb-202) treatment regimens for safety, tolerability and preliminary efficacy in participants with OC and EC; to evaluate the addition of short course of oral corticosteroids following every dose of farletuzumab ecteribulin (MORAb-202) administered every 21 days; and to select treatment regimens with farletuzumab ecteribulin (MORAb-202) for further evaluation in Part B. Part B: to evaluate the safety and tolerability of different doses of farletuzumab ecteribulin (MORAb-202) as monotherapy and in combination with lenvatinib and to determine the recommended dose (RD) of farletuzumab ecteribulin (MORAb-202) as monotherapy and in combination with lenvatinib.

Official Title

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

Conditions

Solid Tumor

Intervention / Treatment

  • Drug: Farletuzumab ecteribulin
  • Drug: Prednisone
  • Drug: Prednisolone
  • Drug: Dexamethasone
  • Drug: Lenvatinib

Other Study ID Numbers

  • MORAb-202-G000-201
  • 2019-003600-12
  • 2023-506868-14
  • 2023
  • 2019

Start Date (Actual)

2020-08-06

Primary Completion Date (Estimated)

2030-08-08

Study Completion Date (Estimated)

2030-08-08

Enrollment (Estimated)

182

Study Type

Interventional

Phase

Phase 1, Phase 2